OV58

Human ovarian serous cancer (ascites) stage III

STR-PCR Data: Amelogenin: X
CSF1PO: 9,12
D13S317: 10,13
D16S539: 12,13
D5S818: 12
D7S820: 10,12
THO1: 9.3
TPOX: 11,12
vWA: 14,17

The OV58 cell line was established from ascitic fluid derived from a 52-year-old female patient diagnosed with ovarian cancer. The tumour was characterised as stage III, serous tumour type. Production of vascular endothelial growth factor (VEGF) has been detected by ELISA. The patient had been treated with carboplatin and subsequently chlorambucil.

DMEM:HAMS F12 (1:1) + 2mM Glutamine + 5% Foetal Bovine Serum (FBS) + 0.5 ug/ml hydrocortisone + 10ug/ml insulin

Split sub-confluent cultures (70-80%) 1:3 to 1:6 i.e. seeding at 2-4x10,000 cells/cm² using 0.25% trypsin/EDTA; 5% CO₂; 37°C.

Cultures from HPA Culture Collections and supplied by Sigma are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.